These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9254338)

  • 21. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in Northern Thailand.
    Thaineua V; Sirinirund P; Tanbanjong A; Lallemant M; Soucat A; Lamboray JL
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):429-42. PubMed ID: 10437936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postexposure prophylaxis for HIV infection.
    Nwokolo NC; Hawkins DA
    AIDS Read; 2001 Aug; 11(8):402-12. PubMed ID: 11570266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Just expensive or also cost effective? Pharmacoeconomic aspects of HIV therapy].
    Glaeske G
    Pharm Unserer Zeit; 2001; 30(3):248-52. PubMed ID: 11400675
    [No Abstract]   [Full Text] [Related]  

  • 26. Seroconversion following nonoccupational postexposure prophylaxis against HIV.
    Roland ME; Neilands TB; Krone MR; Katz MH; Franses K; Grant RM; Busch MP; Hecht FM; Shacklett BL; Kahn JO; Bamberger JD; Coates TJ; Chesney MA; Martin JN
    Clin Infect Dis; 2005 Nov; 41(10):1507-13. PubMed ID: 16231265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness evaluation to inform clinical trial design.
    Ribaudo HJ
    Clin Infect Dis; 2007 Oct; 45(8):1071-3. PubMed ID: 17879927
    [No Abstract]   [Full Text] [Related]  

  • 28. Case studies on nonoccupational postexposure HIV prophylaxis.
    Urbina BY; Merchant RC; Mayer KH
    Med Health R I; 2003 Jun; 86(6):175-7. PubMed ID: 12973889
    [No Abstract]   [Full Text] [Related]  

  • 29. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?].
    Stoll M; Claes C; Schulte E; Körner T; von der Schulenburg JM; Schmidt R
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():45-9. PubMed ID: 10863311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aggressive HIV treatment cost-effective.
    Healthc Benchmarks; 1998 Aug; 5(8):128-9. PubMed ID: 10182003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
    Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
    J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV/AIDS in India. The needle and the damage done.
    Cohen J
    Science; 2004 Apr; 304(5670):509-12. PubMed ID: 15105472
    [No Abstract]   [Full Text] [Related]  

  • 33. A Bayesian approach to net health benefits: an illustration and application to modeling HIV prevention.
    Johnson-Masotti AP; Laud PW; Hoffmann RG; Hayat MJ; Pinkerton SD
    Med Decis Making; 2004; 24(6):634-53. PubMed ID: 15534344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postexposure prophylaxis following HIV exposure.
    Kahn JG; Pinkerton SD; Paltiel AD
    JAMA; 1999 Apr; 281(14):1269-70. PubMed ID: 10208135
    [No Abstract]   [Full Text] [Related]  

  • 36. Research. Daily antiretroviral treatment shown to prevent HIV infections in MSM.
    AIDS Policy Law; 2011 Jan; 26(2):1, 4. PubMed ID: 21344685
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevention. Using early ART to prevent transmission is cost effective.
    AIDS Policy Law; 2014 Feb; 29(3):3. PubMed ID: 24716268
    [No Abstract]   [Full Text] [Related]  

  • 38. Ethical allocation of preexposure HIV prophylaxis.
    Gostin LO; Kim SC
    JAMA; 2011 Jan; 305(2):191-2. PubMed ID: 21224461
    [No Abstract]   [Full Text] [Related]  

  • 39. [Health care methods should be analysed from an ethical perspective].
    Nilstun T; Löfmark R
    Lakartidningen; 2009 Dec; 106(52):3510-2. PubMed ID: 20151511
    [No Abstract]   [Full Text] [Related]  

  • 40. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model.
    Koppenhaver RT; Sorensen SW; Farnham PG; Sansom SL
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):e51-2. PubMed ID: 21921730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.